Abstract
Background. Sirolimus therapy has been used in orthotopic liver transplant (OLT) recipients diagnosed with a variety of diseases; chronic graft rejection (CR), calcineurin associated renal toxicity, preemptive immune suppression, calcineurin related neurotoxicity, preemptive therapy in transplant recipients with history of hepatocellular carcinoma, and steroid resistant allograft rejection. Methods. A search for the medical literature and experiences involving sirolimus was done. Results. Several animal and human reports evaluating the use sirolimus in liver transplant recipients are found and discussed. Conclusion Sirolimus has been used for multitude of indications, primarily based on anecdotal experiences. However, reports of sirolimus related side effects have decreased the transplant communities' enthusiasm towards promoting this agent as a safe immune suppression agent.
| Original language | English |
|---|---|
| Journal | Transplantation Proceedings |
| Volume | 35 |
| Issue number | 3 SUPPL. |
| DOIs | |
| Publication status | Published - May 2003 |
Fingerprint
ASJC Scopus subject areas
- Surgery
- Transplantation
Cite this
Ten years of sirolimus therapy in orthotopic liver transplant recipients. / Neff, G. W.; Montalbano, M.; Tzakis, A. G.
In: Transplantation Proceedings, Vol. 35, No. 3 SUPPL., 05.2003.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ten years of sirolimus therapy in orthotopic liver transplant recipients
AU - Neff, G. W.
AU - Montalbano, M.
AU - Tzakis, A. G.
PY - 2003/5
Y1 - 2003/5
N2 - Background. Sirolimus therapy has been used in orthotopic liver transplant (OLT) recipients diagnosed with a variety of diseases; chronic graft rejection (CR), calcineurin associated renal toxicity, preemptive immune suppression, calcineurin related neurotoxicity, preemptive therapy in transplant recipients with history of hepatocellular carcinoma, and steroid resistant allograft rejection. Methods. A search for the medical literature and experiences involving sirolimus was done. Results. Several animal and human reports evaluating the use sirolimus in liver transplant recipients are found and discussed. Conclusion Sirolimus has been used for multitude of indications, primarily based on anecdotal experiences. However, reports of sirolimus related side effects have decreased the transplant communities' enthusiasm towards promoting this agent as a safe immune suppression agent.
AB - Background. Sirolimus therapy has been used in orthotopic liver transplant (OLT) recipients diagnosed with a variety of diseases; chronic graft rejection (CR), calcineurin associated renal toxicity, preemptive immune suppression, calcineurin related neurotoxicity, preemptive therapy in transplant recipients with history of hepatocellular carcinoma, and steroid resistant allograft rejection. Methods. A search for the medical literature and experiences involving sirolimus was done. Results. Several animal and human reports evaluating the use sirolimus in liver transplant recipients are found and discussed. Conclusion Sirolimus has been used for multitude of indications, primarily based on anecdotal experiences. However, reports of sirolimus related side effects have decreased the transplant communities' enthusiasm towards promoting this agent as a safe immune suppression agent.
UR - http://www.scopus.com/inward/record.url?scp=0037623421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037623421&partnerID=8YFLogxK
U2 - 10.1016/S0041-1345(03)00217-3
DO - 10.1016/S0041-1345(03)00217-3
M3 - Article
C2 - 12742498
AN - SCOPUS:0037623421
VL - 35
JO - Transplantation Proceedings
JF - Transplantation Proceedings
SN - 0041-1345
IS - 3 SUPPL.
ER -